Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI has launched a $400 million funding round and ...
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...
Why you can trust What Hi-Fi? Our expert team reviews products in dedicated test rooms, to help you make the best choice for your budget. Find out more about how we test. What does it take to make a ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results